{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-22-019342","form_type":"8-K","ticker":"MCAG","cik":"0001859035","company_name":"Mountain Crest Acquisition Corp. V","filed_at":"2022-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.808137+00:00","generated_at":"2026-06-21T17:46:30.713597+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Mountain Crest V to combine with AUM Biosciences at ~$400M valuation; PIPE of $30M sought","bullets":["Purchase price of ~$400M; AUM shareholders roll over 100% equity for ~84% of pro forma ownership.","Targeted PIPE of $30M (not committed) to fund AUM balance sheet and transaction expenses.","MCAG cash in trust of $69M; assumes 75% redemptions; $17.25M retained.","AUM is a precision oncology company with pipeline in Phase 2 for AUM001 and AUM601.","Expected close Q1 2023, subject to customary conditions and approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-22-019342","json":"https://secwatch.observer/filing/0001829126-22-019342.json","markdown":"https://secwatch.observer/filing/0001829126-22-019342.md","text":"https://secwatch.observer/filing/0001829126-22-019342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859035/000182912622019342/0001829126-22-019342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859035/000182912622019342/mountaincrest5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T17:46:30.713597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}